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Abstract
Background—An intensive, prospective, open-label pharmacokinetic (PK) study in a subset of 
HIV-infected mothers and their uninfected infants enrolled in the Breastfeeding, Antiretroviral, 
and Nutrition study was performed to describe drug exposure and antiviral response.
Methods—Women using Combivir®[zidovudine (ZDV)+ lamivudine (3TC)]
+Aluvia®[lopinavir/ritonavir(LPV/RTV)] were enrolled. Breast milk (BM) and mother and infant 
plasma (MP, IP) samples were obtained over 6hrs after observed dosing at 6, 12, or 24wks post-
partum for drug concentrations and HIV RNA.
Results—30 mother/infant pairs (10 each at 6, 12,and 24wks post-partum) were enrolled. 
Relative to MP, BM concentrations of ZDV and 3TC were 35% and 21% higher, while LPV and 
RTV were 80% lower. Only 3TC was detected in IP with concentrations 96% and 98% lower than 
MP and BM, respectively. Concentrations in all matrices were similar at 6-24wks. The majority 
(98.3%) of BM concentrations were >HIVwt IC50, with one having detectable virus. There was no 
association between PK parameters and MP or BM HIV RNA.
Conclusions—ZDV and 3TC concentrated in BM while LPV and RTV did not, possibly due to 
protein binding and drug transporter affinity. Undetectable to low ARV concentrations in IP 
suggests prevention of transmission while breast feeding may be due to ARV effects on systemic 
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or BM HIV RNA in the mother. Low IP 3TC exposure may predispose an infected infant to HIV 
resistance, necessitating testing and treating infants early.
Introduction
Breastfeeding by HIV infected mothers places the infant at risk of transmission; however, 
formula feeding increases the risk of infant morbidity and mortality during the first 6 months 
post-partum [1,2]. UNAIDS has reported that antiretroviral use in mothers is much lower in 
the breastfeeding period (49%), as compared to pregnancy and delivery (62%) [3]. This is 
especially concerning since up to 40% of mother-to-child transmission to infants occurs 
during breastfeeding [3]. The results of several large randomized trials and observational 
studies have demonstrated substantially reduced transmission by either providing pre-
exposure prophylaxis to the uninfected breastfeeding baby with antiretrovirals (ARVs), or 
by providing combination ARV therapy (ART) to the breastfeeding mother [1,2, 4-14]. With 
these interventions, the World Health Organization (WHO) has proposed to decrease MTCT 
to 5% and ensure 90% of breastfeeding infant-mother pairs receive antiretroviral therapy or 
prophylaxis by 2015.
The BAN (Breastfeeding, Antiretrovirals, and Nutrition) Study showed a decrease of HIV 
transmission during 28 weeks of breastfeeding with either daily nevirapine given to 
breastfeeding infants (74% protective efficacy) or combination ART given to the mother 
(53% protective efficacy). Based on the results of BAN and other studies, the WHO now 
recommends the use of triple ART to the mother and 4-6 weeks of peripartum daily 
nevirapine or zidovudine to the infant [15].
The efficacy of combination ART given to the breastfeeding mother is likely due to a 
combination of suppressed HIV replication in both blood and breast milk. Previous studies 
of ARV exposure in maternal plasma and breast milk [16-21] have shown differing 
penetration of antiretroviral drugs into the breast milk. This has potential advantages and 
disadvantages. ARVs that concentrate in breast milk may have the advantage of directly 
suppressing viral replication in the breast and/or transferring a large enough drug dose to the 
breastfeeding infant to provide a local protective effect, but may have a disadvantage of 
ARV-induced side effects in the infant. ARVs that enter breast milk may cause selective 
pressure on replicating HIV in the breast, resulting in the development of resistance.
The extent of ARV penetration into breast milk, and into the breast feeding infant, is 
currently only estimated by sparse sampling investigations at single time points. Drug 
exposure over a dosing interval for breastfeeding infants and their mothers taking 
antiretroviral drugs is unknown. Limited but promising data on the systemic and local 
effects of ARV exposure on HIV RNA in breastfeeding women has been described in one 
study [21]. This investigation evaluated HIV RNA and multiple dose pharmacokinetics (PK) 
of zidovudine, lamivudine, lopinavir, and ritonavir in maternal plasma (MP), breast milk 
(BM), and infant plasma (IP) over 6 hours in 30 HIV-infected mothers and breastfeeding 
HIV-uninfected infants participating in the BAN Study at 6, 12, and 24 weeks post-partum.
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This was a prospective, non-blinded, steady-state intensive PK and HIV RNA investigation 
in a subset of mother/infant pairs enrolled in the BAN study.
Study Population
A convenience sample of 30 mother-infant pairs was recruited from the 849 pairs 
participating in the BAN study that had been randomized to the maternal ARV arm. All 
mothers were HIV infected with CD4+ T cell counts > 200 cells/mm3 and all infants were 
HIV uninfected. Each mother was given a single dose of nevirapine (sdNVP) prior to 
delivery. Additionally, all mothers initiated zidovudine (ZDV)+lamivudine (3TC) (1 
combination tablet = ZDV 300mg + 3TC 150mg; Combivir®) and 2 tablets of lopinavir 
(LPV)+ ritonavir (RTV) (1 combination tablet = LPV 200mg + RTV 50mg; Aluvia®) twice 
daily just after delivery. Therapy was prescribed until the cessation of breastfeeding for a 
maximum of 28 weeks.
Study Procedure
The protocol was approved by the Institutional Review Boards of the US Centers for 
Disease Control and Prevention, the University of North Carolina at Chapel Hill, and the 
National Health Sciences Research Committee of Malawi [UNC IRB 03-MED-184]. Each 
mother was approached and agreed to participate at either 6, 12, or 24 weeks post partum. 
Mothers recorded the date and time of ARV administration for 3 days prior to their 
scheduled PK visit. As overnight visits could not be accommodated at the site in Malawi, an 
abbreviated 6-hour PK visit followed a morning dose. Subjects were instructed to report to 
the UNC Project building in the morning prior to their dose and 10-11 hours after their 
previous evening dose. An intravenous catheter was placed and normal saline was 
administered to keep the line patent. Prior to the mother's morning dose of ARVs (t=0hr), 
5mL of whole blood and 10mL of breast milk from the mothers, and 3mL of infant whole 
blood were collected. Breast milk was collected from the right breast unless clinically 
contraindicated at which time it was collected from both breasts and labeled as right or left 
breast. One tablet of Combivir® and 2 tablets of Aluvia® were administered and plasma 
(MP and IP) and breast milk samples were obtained at 2, 4, and 6 hours after these witnessed 
doses. Infants were allowed to breastfeed as often as needed and mothers were allowed to 
eat after the t=0 and 6hr blood draws. Breakfast and lunch selections were similar for all 
subjects, consisting of bun and tea for breakfast and nsima and chicken for lunch (local 
foods in Malawi).
As a control comparison for HIV RNA in breast milk, 10 mothers randomized to the infant 
nevirapine arm (i.e., mothers were not on ART) while enrolled in the BAN study were 
selected. Daily nevirapine was only given to their infants. Breast milk samples from these 
women were also taken at 6, 12, and 24 weeks post-partum for evaluation. In addition, 
historical control data from a Western population of both HIV infected patients and health 
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volunteers including men and women for each antiretroviral were included for a qualitative 
comparison.
Drug Assays from Blood and Breast Milk
All whole blood samples were collected in K3 containing Vacutainer tubes (Fisher 
Scientific, Hampton, New Hampshire, USA) and centrifuged at 2600rpm at 4°C for 10 
minutes. Plasma was removed and aliquoted to 2mL cryovials and stored at -70°C until 
shipped to the UNC Center for AIDS Research Clinical Pharmacology and Analytical 
Chemistry lab for analysis. Drug concentrations for ZDV, 3TC, LPV, and RTV in plasma 
and breast milk were analyzed using a validated HPLC-MS/MS method [22]. Briefly, drugs 
were extracted from 50-100uL of plasma and 200μL of whole breast milk. A solid-phase 
extraction procedure (BOND ELUT-C18, Harbor City, California, USA) was used with a 
90:10 methanol:water solution as the eluent. Eluted samples were dried at 40°C under a 
gentle steam of nitrogen and reconstituted in 100μL of mobile phase before using a LEAP 
HTC Pal thermostated autosampler to inject the samples onto an Applied Biosystems API 
4000 triple quadruple mass spectrometer. Antiretrovirals were separated using an Aquasil 
C18 column (Thermo-Electron, San Jose, CA). Analyst 1.3.1 software was used for data 
collection. The concentration range for all ARVs was 10-10,000 ng/mL, with an intra-and 
inter-day precision and accuracy falling within 15%. The laboratory participates in two 
external proficiency testing programs twice annually: the Division of AIDS Clinical 
Pharmacology Quality Assurance Program, and the Dutch Association for Quality 
Assessment in TDM and Clinical Toxicology (KKGT) International and Interlaboratory QC 
Program [23, 24].
HIV RNA Assays from Blood and Breast Milk
HIV RNA was measured in 0.6ml plasma or whole breast milk using the Abbott RealTime 
HIV-1 assay. Breast milk was pre-treated by adding 0.21ml Promega RNA Lysis Buffer and 
0.06ml Proteinase K (Abbott) to 0.6ml whole breast milk, then incubating at 53°C for 20 
min. The breast milk mixture was extracted the same as for plasma.
Statistical Analysis
Non-compartmental methods were employed to calculate pharmacokinetic parameters using 
WinNonlin Pro 4.0.1 (Pharsight Corp, Mountain View, California, USA). AUC0-6hr (area 
under the concentration time curve from 0 to 6 hrs post dose) was calculated using the linear 
up/log down trapezoidal rule. Since several of the plasma C0hr,ss (steady state concentrations 
just prior to the dose) (4.8% from ZDV, 0.4% from 3TC, 0.8% from LPV and 1.5% from 
RTV) were undetectable, likely due to the variability of the length of time that elapsed from 
the previous dose to sampling, Cavg (average concentration over the sampling time) was 
used in the statistical analyses in lieu of the trough concentration. The median (range) 
elapsed time from previous dose to sampling was 14.9 (13-17) hrs, which were all outside 
the range of the dosing interval. Cavg was calculated by dividing the AUC by the time 
interval over which the AUC was calculated. ARV adherence rates were determined based 
on diary cards, and self-reported adherence assessments taken at 1, 4, 8, 21, and 28 weeks. 
Median and interquartile range (IQR) were calculated for all demographic data, PK 
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parameters, and PK parameter ratios. Associations of drug concentrations between 
compartments and over time were analyzed using linear regression [SAS Version 9.2].
HIV RNA was quantified as copies/mL, assessed as a continuous variable and categorized 
as detectable (MP viral load (VL) ≥ 40; BM VL ≥ 56) or undetectable (MP VL < 40; BM < 
56). HIV RNA concentrations that were detected but below the lower limit of quantification 
were imputed to 50% of the lower limit of quantification (MP VL = 20; BM VL = 28). PK 
parameters were assessed as continuous variables and were dichotomized using the 
following cut-points: median, geometric mean, 25th percentile, and 75th percentile.
Descriptive statistics were computed for PK parameters from each antiretroviral drug and 
viral load type (maternal plasma and breast milk). Viral load and PK parameters were 
compared with adherence data. Percent adherence was assessed as a continuous variable, 
and dichotomized by having either reported“all ARV doses taken prior to visit” at week 1, 4, 
8, 21, and 28 (100%) or “some doses missed” prior to at least one of the aforementioned 
weeks (<100%). Weeks were chosen based on available adherence assessments conducted in 
the BAN study. Fisher's exact tests were used to test for an association between detectable 
versus undetectable MP HIV RNA and BM HIV RNA.
Differences in breast milk HIV RNA by study arm (maternal ARV versus infant NVP) were 
assessed using Fisher's exact tests and generalized estimating equations with an 
exchangeable correlation matrix. For the maternal arm single time points for HIV RNA were 
available; however, multiple time points were utilized for the infant NVP arm. For the 
purposes of modeling, HIV RNA was log10 transformed when used as a continuous 
outcome. Unadjusted linear regression, exact logistic regression, and Fisher's exact tests 
were used to look at the association between PK parameters and viral load.
Results
Thirty mother-infant pairs were enrolled for PK evaluation (10 at each of 6, 12, and 24 
weeks postpartum). The median (IQR) for characteristics of the mother/infants pairs 
included: maternal age=25 (23,29) yrs; maternal weight=53 (51,59) kg; maternal CD4+ T 
cell count at screening (≤ 30 weeks gestation) =431(345,576) cells/mm3; HIV RNA at 
screening =5201 (1384,22461) copies/mL; infant birth weight=3 (2.7,3.4) kg; and 17 infants 
were male. There were no demographic differences between the women at the three time 
points postpartum. All women were 100% adherent based on diary cards for three days prior 
to the study visit. Infants were fed a median of 6 times per study visit with a range of 2 to 20 
minutes at each feeding. PK parameters are presented in Table 1 and graphically represented 
in Figure 1.
ZDV concentration-time profiles are shown in Figure 1a. Thirty percent (10/30) of ZDV 
maternal plasma concentrations at t=0 were below the limit of detection. Of all the 
detectable concentrations from all time points, exposures in BM were 35% higher than in 
MP. There was no detectable ZDV in infants. PK parameters for ZDV did not differ over the 
6, 12, and 24 week time periods (p=0.78 and 0.68 for MP and BM, respectively). Of the 
detectable MP and BM ZDV concentrations, only 4.8% (5/105) and 0.8% (1/118) were 
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below the HIVwt IC50, respectively (5ng/mL). ZDV AUC and Cavg for mothers’ plasma 
were similar to historic control data in 24 healthy Western volunteers [25]. Statistical 
comparisons were not made since the original dataset was not available.
3TC concentration-time profiles are shown in Figure 1b. Only 6% (2/30) of MP 3TC 
concentrations at t=0 were undetectable. Of all the detectable 3TC concentrations for all 
time points, exposure in BM was 21% higher than in MP. 3TC concentrations were 
detectable in 93% (107/115) of infant plasma samples, which was 2% and 3.7% of BM and 
MP, respectively. PK parameters for 3TC did not differ across post-partum weeks (p=0.33 
and 0.31 for MP and BM, respectively). Of the detectable MP, BM, and IP concentrations, 
5.3%, 3.3%, and 83% were below the HIVwt IC50 for wild type virus, respectively (100ng/
mL). No infant had concentrations consistently above the IC50 over the 6 hr sampling 
interval. Concentrations in mothers’ plasma were similar to historic controls [25].
LPV concentration-time profiles are shown in Figure 1c. Sixteen percent (5/30) of MP 
concentrations and 13% (4/30) BM concentrations obtained at t=0h were undetectable. 
Lopinavir AUC and Cavg in BM were 80% lower than in MP. There were no detectable LPV 
concentrations in infants’ plasma. PK parameters for LPV were not different across time 
post-partum (p=0.99 and 0.56 for MP and BM, respectively). Of the detectable MP and BM 
concentrations, 1.8% and 0% were below the HIVwt IC50, respectively (2ng/mL). 
Concentrations in the maternal plasma were similar to historic controls [26].
RTV concentration-time profiles are shown in Figure 1d. Thirteen percent (4/30) of MP 
concentrations and 16% (5/30) BM concentrations obtained at t=0 were undetectable. 
Exposures in BM were 80% lower than in MP. There were no detectable RTV 
concentrations in infants’ plasma. A 52% decrease in BM concentrations was noted from 6 
to 24 weeks post-partum which could be interpreted as clinically significant; however, was 
not statistically significant (p=0.21). No changes occurred in the RTV exposure in MP 
(p=0.79). Of the detectable MP and BM concentrations, 0 and 2.7% were below the HIVwt 
IC50, respectively (10ng/mL). RTV concentrations in mothers’ plasma were approximately 
30% lower than historic controls [27].
Association Between Breast milk and Mothers’ Plasma
Combining all paired MP-BM concentrations from all time points, breast milk exposures for 
each drug were correlated with maternal plasma (Figure 2). Pearson correlation coefficients 
(rho) for ZDV, 3TC, LPV, and RTV were 0.86, 0.51, 0.54, 0.74, respectively (p value 
<0.0001 for all).
Associations of Drug Concentrations, Adherence, and Viral Load
HIV RNA was detected in 34% (10/29) of mothers’ plasma samples with a median (range) 
of 393 (54-49,708) copies/mL. The median (range) for all mothers’ plasma HIV RNA was 
20 (<40 - 49,708) copies/mL. The median of 20 copies/mL was an imputed value and 
represented those samples with HIV RNA >0 but ≤40 copies/mL. In breast milk, HIV RNA 
was detected in 3% (1/30) of samples, hence no association was found with plasma (p>0.9). 
Utilizing logistic regression, there were no significant associations between MP PK 
parameters and HIV RNA. Estimated odds ratios (95% CI) for the association between drug 
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AUC > the AUC geometric mean and having detectable HIV RNA in MP ranged from 0.73 
(0.16-3.39) for 3TC to 1.70 (0.33-8.67) for LPV. However, both MP and BM PK parameters 
appeared to be higher in patients with undetectable HIV RNA compared to those with 
detectable HIV RNA.
A large number of undetectable BM viral loads precluded us from detecting an association 
between BM HIV RNA and antiretroviral exposure. Therefore, we further explored the 
exposures of each antiretroviral agent relative to their HIVwt IC50 for the ability to predict 
HIV RNA response. The Cavg concentration in mothers’ plasma and breast milk for all 
antiretrovirals was > HIVwt IC50, although not all concentrations at all time points were > 
HIVwt IC50,. Despite this, only 19/29 mothers had MP viral loads < 40 copies/mL.
A total of 25 breast milk viral loads were obtained from 10 mothers in the control arm 
(infant nevirapine arm) at 6, 12, and 24 weeks post-partum in order to have a comparison of 
breast milk viral loads within the same study in a similar population. Ninety percent (9/10) 
of mothers in the control arm had at least one detectable breast milk viral load while only 
3% (1/30) in the maternal ARV arm had detectable breast milk viral load confirming the 
effectiveness in this investigation of women for antiretroviral based suppression of HIV 
RNA in breast milk.
Self-reported adherence to antiretrovirals did not predict either drug exposure or HIV RNA. 
Adherence immediately prior to each PK visit was 100% for each subject. A median of five 
adherence assessments for each mother over the 24-week study visits was utilized to 
determine overall adherence. Among the 30 women in the maternal ARV arm, twenty-four 
mothers had 100% overall adherence (optimal adherence group) in the BAN study with the 
other 6 mothers having 60-80% adherence (sub-optimal adherence group). There were no 
differences between the median Cavg (or AUC) for any of the antiretrovirals for the optimal 
vs the suboptimal adherence groups [ZDV=97 vs 121 ng/mL p=0.1; 3TC=626 vs 667 ng/mL 
p=0.6; LPV 8364 vs 7474 ng/mL p>0.9; RTV 393 vs 360 ng/mL p>0.9, respectively]. 
Additionally, there was no difference in the number of detectable viral loads in the sub-
optimal adherence group vs the optimal adherence group for MP [16% (1/6) vs 39% (9/23); 
p=0.6] or BM [16% (1/6) vs 0% (0/24); p=0.2], respectively.
Discussion
This investigation supports previous reports of higher ZDV and 3TC exposure in breast milk 
compared to blood plasma, while LPV and RTV have lower penetration into breast 
milk[16-18, 20]. The magnitude of ZDV and 3TC exposures with single point 
concentrations have ranged from 186-557% plasma[16-18, 20], while this intensive PK 
evaluation found the range of exposure to be less variable at 121-135% when an abbreviated 
AUC sampling strategy was used. In previous studies including some of our own, single 
point sampling of LPV and RTV BM exposures have been reported to be 1-32% of plasma, 
while in this investigation we found them to be 10-39% of plasma with more intensive 
sampling [16]. Therefore, although qualitative evaluations of breast milk penetration can be 
made from single-time point studies, we have demonstrated here that more extensive 
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sampling is required to provide accurate, less variable data on the magnitude of drug 
exposure.
Antiretroviral concentrations are not always detected in the plasma of breastfeeding infants 
whose mothers are utilizing antiretrovirals. ZDV and protease inhibitors have been 
inconsistently detected in infant plasma[16-18, 20, 21]. Nevirapine and efavirenz exposures 
were found to be in four studies 12-60% of mothers’ plasma concentrations [17-20]. Data in 
this investigation showed only 3TC concentrations detectable in infant plasma at 2% of the 
concentration in breast milk and at 3.7% of the concentration in mothers’ plasma. This is 
similar to past reports of 3TC exposure in breastfeeding infants at 1-6% of concentrations 
seen in mothers’ plasma[16-18, 20].
For the benefit of future studies investigating breast milk concentration of these drugs as a 
predictor of outcomes, we conclude that BM concentrations are correlated with MP for all 4 
ARVs tested (r=0.51-0.86). The relationship for all 4 drugs was linear, and we did not see 
any saturable pharmacokinetic relationship within the exposures measured, or dichotomous 
results suggesting altered mechanisms of drug distribution. The finding of nucleoside 
reverse transcriptase inhibitors concentrating in breast milk and the protease inhibitors 
achieving very low exposure in breast milk suggests drug specific factors likely play a role. 
Multiple characteristics contribute to the degree of exposure in breast milk including degree 
of protein binding, lipo- or hydrophilicity and ionization [28]. Overall the plasma protein 
binding has been the best predictor of breast milk penetration where the higher the protein 
binding the less penetration into breast milk[28,29]. In vitro and in vivo evaluations have 
concluded that large intra- and inter-subject variability exists for breast milk drug 
concentrations compared to mothers plasma. Previous data has suggested that the infant 
plasma concentrations serve as predictors of exposure in breast milk; however, data from 
this investigation would not support this finding as minimal drug exposure is seen in infant 
plasma [28]. Additionally, drug transporters have been identified in breast tissue, including 
MRP1, OCT1, and OCT3; however, expression of MRP4 has not been identified [30,31]. 
Lopinavir and ritonavir are substrates for MRP1 while ZDV and 3TC are substrates for 
MDR4 [32]. Additionally, 3TC is a substrate of OCT1 and 3. We theorize that the presence 
of MRP1 is effluxing LPV and RTV away from the breast milk while the absence of MRP4 
is allowing the penetration of ZDV and 3TC into breast milk. Additionally, OCT1 and 3 
may be facilitating the transport of 3TC into breast milk. This theory would need to be 
validated to confirm this mechanism.
There was a clear difference in the HIV RNA measured in the BM of mothers on ART and 
those that were not (97% vs 40% undetectable, respectively). The number of mothers with 
undetectable HIV RNA in plasma compared to breast milk was also quite different (65% vs 
97% undetectable, respectively). In general, BM HIV RNA is 2-3 logs lower than matched 
plasma and highly correlated [32]. Limited data exist on the degree of breast milk viral load 
decline secondary to antiretroviral therapy [21]. For mothers taking ART the average HIV 
RNA in MP was 3.30log vs 0.77log in BM (2.53 log difference), which is consistent with 
previously reported data [32]. The exact mechanism of HIV transmission through breast 
milk is somewhat unclear but is believed to involve both cell free and cell associated virus 
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[32]. Inter-subject changes in antiretroviral exposures and viral loads over the 24-week post 
partum period were evaluated. No significant changes in MP or BM exposure were noted.
Since a large number of breast milk viral loads were undetectable, the correlation of breast 
milk viral load and concentration was not evaluated. Concentrations in mother's plasma 
relative to HIVwt IC50 did not seem to predict undetectability of virus in the plasma. The 
lack of correlation may simply be secondary to the small sample size or to the large 
interpatient variability typically seen with antiretroviral concentrations. The only other study 
that has collected information on antiretroviral concentrations in breast milk and viral load 
did not report whether or not these correlated [21].
Since adherence to study medications obtained from 3-day medication diaries was reported 
to be 100% for all subjects, this was not used to assess drug exposure or efficacy. Overall 
median adherence in the BAN study over 24 weeks for these 30 subjects was 60-100% 
based on self-reported adherence questionnaires at 5 scheduled study visits during the 24-
week period. Therefore, this measure was utilized in further comparisons. There did not 
appear to be an association between adherence and PK parameters, likely due to the small 
sample size and high rate of overall adherence. It should be noted that self-reported 
adherence may have overestimated the actual adherence and could be considered a 
limitation of the study.
In conclusion, antiretroviral penetration into breast milk is higher for ZDV and 3TC and 
lower for LPV and RTV compared to mothers’ plasma. This is likely due to higher protein 
binding of lopinavir and ritonavir compared to zidovudine and lamivudine as well as the 
potential for differences in drug transporter affinities. Additionally, this study has shown 
that greater variability exists in using single paired PK time points to predict the ARV 
exposure in breast milk [ZDV,3TC=186-557% vs 121-135% of mother's plasma; 
LPV,RTV=1-32% vs 10-39% of mother's plasma], and sampling over a dosing interval 
should occur at the outset of a breast milk PK study to avoid misleading results. However, 
we did note that a linear relationship could be developed for drugs with this information and 
sparse plasma sampling utilized in future investigations to estimate breast milk 
concentrations. Concentrations in mothers’ plasma and breast milk were not markedly 
different between 6, 12, and 24 weeks post-partum. Therefore, drug exposure can likely be 
studied at any timeframe from 6 weeks to 6 months post-partum and yield accurate 
assessments. In these mothers taking combined antiretroviral therapy, only one breast milk 
HIV RNA was greater than 40 copies/mL. These data, taken with the low to undetectable 
ARV exposure in infants, suggest that antiretroviral therapy given to mothers during breast 
feeding is effective at suppressing breast milk viral load which in turn will have an effect on 
MTCT by rendering the mother less infectious. Low extracellular concentrations in the 
infant seen in this investigation would not suggest protection of the infant if exposed to 
virus; however, multiple mechanisms for protection are unknown from this data including 
infant intracellular antiretroviral concentrations. Low 3TC concentrations in infants may 
predispose infected infants to HIV resistance via selective drug pressure or resistant virus 
from the mother could be transmitted to the infant via breastfeeding. Therefore, it is 
important to test breastfeeding infants early for HIV in mothers who are taking 
antiretrovirals to limit the possibility of viral resistance.
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Median (IQR) Zidovudine Concentation vs Time Profile
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Median (IQR) Lamivudine Concentration vs Time Profile
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Median (IQR) Lopinavir Concentration vs Time Profile
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Median (IQR) Ritonavir Concentration vs Time Profile
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Correlations Between Breast Milk Concentrations and Mothers’ Plasma Concentrations
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Table 1
Median (IQR) Antiretroviral PK Parameters (N=samples with detectable concentrations/total samples)
ZDV 3TC LPV RTV
Cavg (ug/mL) AUC0-6hr (hr*ug/mL) Cavg (ug/mL) AUC0-6hr (hr*ug/mL) Cavg (ug/mL) AUC0-6hr (hr*ug/mL) Cavg (ug/mL) AUC0-6hr (hr*ug/mL)
Mothers' plasma 0.143 (0.107,0.192) N=105/115 0.879 (0.686,1.205) 0.717 (0.588, 
0.945) 
N=113/115
4.36 (3.47, 5.67) 7.79 (4.51, 
10.13) 
N=110/115




Breast Milk 0.2 (0.119,0.263) N=98/121 1.201 (0.781,1.576) 0.944 (0.682, 
1.112) 
N=107/121
5.70 (4.29, 6.70) 1.43 (0.705, 
2.07) 
N=117/121




Infant Plasma ND N=0/115 ND 0.018 (0.010, 
0.028) 
N=107/115
0.121 (0.074, 0.150) ND N=0/115 ND ND N=0/115 ND
BM/MP 1.35 (1.02, 1.63) 1.21 (1.06, 1.57) 0.194 (0.136, 0.267) 0.195 (0.159, 0.243)
IP/BM NA 0.02 (0.013, 0.027) NA NA
IP/MP NA 0.025 (0.017, 0.035) NA NA
ND = not detected; NA= not applicable; BM/MP=ratio of all BM and MP concentrations; IP/BM=ratio of all IP and BM concentrations; IP/
MP=ratio of all IP and MP concentrations
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